Dec 3, 2019 | Frontpage, Gallery, Impact, News, Translation
Veteran entrepreneurs and cofounders of Actuate Therapeutics, Inc., Daniel Schmitt and Andrew Mazar, PhD, are taking no chances with their lead clinical candidate 9-ING-41, a promising new treatment for advanced and drug-resistant cancers and select inflammatory...
Jun 19, 2019 | Frontpage, Gallery, Impact, News, Newsletter 2019 Summer, Translation
A major dilemma faced by many people undergoing chemotherapy for cancer is whether the drugs will cause more harm than good. “Chemotherapeutic drugs can have serious side effects. Some of the adverse events in chemotherapy, such as heart failure, can even take as long...
Nov 1, 2018 | Gallery, Impact, News
Vadim Backman, CLP resident member and Walter Dill Scott Professor of Biomedical Engineering, is featured on the Fall 2018 cover of Northwestern magazine. The story explains Backman’s path-breaking work in chromatin regulation to fight resistance in cancer and...
Oct 17, 2018 | Gallery, News
An inexpensive drug for Type 2 diabetes also decreases the risk of heart attacks and strokes caused by air pollution, according to a new Northwestern Medicine study. The drug, metformin, is already used by more than 100 million people worldwide to treat diabetes. A...
Sep 26, 2018 | Gallery, News, September Newsletter
When Patrick Martin, Managing Director, Martin Investment Management, LLC, first heard about the idea to form a new institute at Northwestern University that would combine the strengths of different fields of study into one effort focused on finding new drugs and...
Sep 26, 2018 | Gallery, News, September Newsletter
One of the most intractable obstacles in treating and curing cancer is the tumor’s ability to adapt to and resist treatments. Although many new and effective drugs are available, according to the National Cancer Institute, “nearly all current treatments face the same...
